Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Cost of sales by Year
Cost of sales — Royalty expense (CFF & third-party royalties, $M) ($M)
Vertex Pharmaceuticals Cost of sales: $1,050M in FY2025, up 3.5% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Note (Segment Reporting — Significant Segment Expenses).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cost of sales — Royalty expense (CFF & third-party royalties, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,050 | +3.5% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 1,014 | +11.1% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 913 | +11.4% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 820 | – | Form 10-K (filed 2025-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 2.40 | -33.3% | Form 10-K (filed 2018-02-15) ↗ |
| FY2016 | Dec 31, 2016 | 3.60 | -51.4% | Form 10-K (filed 2018-02-15) ↗ |
| FY2015 | Dec 31, 2015 | 7.40 | – | Form 10-K (filed 2018-02-15) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Cost of sales ($M), annual FY2015–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/seg-cogs-royalty
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.